We are live on ! Find out more
NAMS icon

NewAmsterdam Pharma
NAMS

100 hedge funds and large institutions have $1.28B invested in NewAmsterdam Pharma in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 17 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,723% more call options, than puts

Call options by funds: $1.09M | Put options by funds: $60K

165% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 17

110% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 10

11% more funds holding

Funds holding: 90 → 100 (+10)

5.62% more ownership

Funds ownership: 80.02% → 85.64% (+5.6%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

7% less capital invested

Capital invested by funds: $1.38B → $1.28B (-$104M)

Holders
100
Holders Change
+10
Holders Change %
+11.11%
% of All Funds
1.44%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
21
Increased
45
Reduced
17
Closed
10
Calls
$1.09M
Puts
$60K
Net Calls
+$1.03M
Net Calls Change
+$1.08M

Top Buyers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
+$11.8M
2
FLSM
Frazier Life Sciences Management
California
+$10.9M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$9.01M
4
PCH
Polar Capital Holdings
United Kingdom
+$8.69M
5
RSCM
Rock Springs Capital Management
Maryland
+$6.11M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$19.9M
2
AG
Artal Group
Luxembourg
-$15.4M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.6M
4
SCM
Superstring Capital Management
New York
-$1.23M
5
GC
GMT Capital
Georgia
-$1.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$5.48M +$1.5M +86,712 +36%
Alyeska Investment Group
27
Alyeska Investment Group
Illinois
$5.12M +$3.85M +222,517 +260%
EP
28
Eversept Partners
New York
$5.1M -$390K -22,533 -7%
DFO
29
Duquesne Family Office
New York
$4.77M +$4.97M +287,535 New
TCM
30
TimesSquare Capital Management
New York
$4.24M +$158K +9,160 +4%
Ensign Peak Advisors
31
Ensign Peak Advisors
Utah
$4.08M -$9.26K -535 -0.2%
UBS AM
32
UBS AM
Illinois
$3.97M +$3.83M +221,305 +1,231%
Two Sigma Investments
33
Two Sigma Investments
New York
$3.82M +$2.49M +143,800 +167%
MAP
34
Moody Aldrich Partners
Massachusetts
$3.59M -$72.2K -4,174 -2%
Morgan Stanley
35
Morgan Stanley
New York
$3.37M +$3.09M +178,513 +723%
HP
36
HealthInvest Partners
Sweden
$2.31M +$1.09M +63,189 +83%
UBS Group
37
UBS Group
Switzerland
$2.16M +$2.15M +124,171 +2,046%
Aberdeen Group
38
Aberdeen Group
United Kingdom
$2.14M +$918K +53,060 +70%
RAM
39
Readystate Asset Management
Illinois
$2.01M +$2.09M +121,000 New
Marshall Wace
40
Marshall Wace
United Kingdom
$1.83M +$1.53M +88,293 +404%
PHP
41
Parkman Healthcare Partners
Connecticut
$1.75M -$520K -30,042 -22%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$1.62M +$1.69M +97,500 New
BBA
43
Baker Bros. Advisors
New York
$1.61M -$2.01K -116 -0.1%
Wellington Management Group
44
Wellington Management Group
Massachusetts
$1.53M +$159K +9,162 +11%
Geode Capital Management
45
Geode Capital Management
Massachusetts
$1.43M +$24.2K +1,399 +2%
CP
46
CenterBook Partners
Connecticut
$1.42M +$1.48M +85,695 New
AA
47
ALPS Advisors
Colorado
$1.16M +$1.21M +69,660 New
BlackRock
48
BlackRock
New York
$1.11M +$433K +25,028 +60%
CCM
49
Cinctive Capital Management
New York
$1.11M +$504K +29,115 +78%
GCP
50
GSA Capital Partners
United Kingdom
$1.1M +$510K +29,496 +80%
1
2
3 4 5

NAMS Hedge Fund Activity: Q3 2024 in Review

100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q3 2024, worth a combined $1.28B — down 7.5% from $1.38B a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new NAMS positions and 10 closed out — a net gain of 11 holders — while 45 added to existing stakes and 17 trimmed.

The largest buyer was Woodline Partners, adding an estimated $11.8M. The largest seller was Millennium Management, cutting an estimated $19.9M.

  • 100 institutional investors held NewAmsterdam Pharma (NAMS) as of Q3 2024, up from 90 in Q2 2024.
  • Funds reported $1.28B of NewAmsterdam Pharma stock for Q3 2024, down 7.5% quarter-over-quarter.
  • 21 funds opened new NewAmsterdam Pharma positions in Q3 2024 and 10 closed out, a net change of +11 holders.
  • The largest NewAmsterdam Pharma buyer in Q3 2024 was Woodline Partners, an estimated $11.8M added.
  • The largest NewAmsterdam Pharma seller in Q3 2024 was Millennium Management, an estimated $19.9M sold.

Based on aggregated 13F filings for Q3 2024.